Glaxo battles IRS over big tax burden

Source: Agencies | May 25, 2009, Monday |

Print Edition

BRITISH-BASED drug company GlaxoSmithKline is battling the United States Internal Revenue Service over a potential US$1.9 billion in back taxes, interest and penalties.

Glaxo had already detailed the dispute in its annual report in March, but the case was highlighted by The Wall Street Journal, which said the IRS was investigating a tax-savings technique employed by the company known as "earnings stripping."

The practice usually involves reducing taxable profits in the US by claiming excessive interest deductions on intercompany loans from units abroad.

Glaxo, the world's second-largest drug maker, said in the annual report that in this case the dispute arose over its "reclassification of an inter-company financing arrangement ... from debt to equity and its consequent recharacterization of the amounts paid as dividends subject to withholding tax."

Manufacturing

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Glaxo battles IRS over big tax burden

Email this to your friend